Cargando…

Medical Management of Functioning Pituitary Adenoma: An Update

The treatment of functioning pituitary adenoma (FPA) must achieve endocrinological remission as well as tumor size reduction. The first-line treatment of FPA except prolactinoma is transsphenoidal surgery (TSS). Medical treatments and/or radiation will be applied as adjuvant therapies succeeding to...

Descripción completa

Detalles Bibliográficos
Autor principal: OKI, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japan Neurosurgical Society 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4533360/
https://www.ncbi.nlm.nih.gov/pubmed/25446388
http://dx.doi.org/10.2176/nmc.ra.2014-0239
_version_ 1782385317871878144
author OKI, Yutaka
author_facet OKI, Yutaka
author_sort OKI, Yutaka
collection PubMed
description The treatment of functioning pituitary adenoma (FPA) must achieve endocrinological remission as well as tumor size reduction. The first-line treatment of FPA except prolactinoma is transsphenoidal surgery (TSS). Medical treatments and/or radiation will be applied as adjuvant therapies succeeding to TSS. In patients with prolactinoma, dopamine agonists, especially cabergoline, are quite efficient. Dopamine agonists decrease plasma prolactin levels and induce shrinkage in most patients and can be ceased in some of them. In patients with acromegaly, dopamine agonists, somatostatin analogues, and growth hormone receptor antagonist have been used as a monotherapy or the combination, and the high remission rate can be achieved. Pasireotide having high affinity to type 5 somatostatin receptors will be available for the patients presenting resistance against type 2 receptor agonists, such as octreotide and lanreotide. The preceding treatment with somatostatin analogues is beneficial for improving the success rate of TSS. The chimera compounds of somatostatin analogues and dopamine agonists have been investigated. The medical treatments of Cushing's disease are challenging, if TSS is not successful. To suppress ACTH secretion, dopamine agonists and somatostatin analogues have been examined, but neither came to show a sufficient effect. Pasireotide reduces urinary cortisol excretion with a high remission rate. Adrenal enzyme inhibitors (AEIs), such as metyrapone, can inhibit cortisol synthesis form adrenal glands promptly and sufficiently in most of patients. LCI699, a newly developed AEI, is more potent than metyrapone and will be available. We should use available medical treatments for improving the prognosis and quality of life.
format Online
Article
Text
id pubmed-4533360
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher The Japan Neurosurgical Society
record_format MEDLINE/PubMed
spelling pubmed-45333602015-11-05 Medical Management of Functioning Pituitary Adenoma: An Update OKI, Yutaka Neurol Med Chir (Tokyo) Review Article The treatment of functioning pituitary adenoma (FPA) must achieve endocrinological remission as well as tumor size reduction. The first-line treatment of FPA except prolactinoma is transsphenoidal surgery (TSS). Medical treatments and/or radiation will be applied as adjuvant therapies succeeding to TSS. In patients with prolactinoma, dopamine agonists, especially cabergoline, are quite efficient. Dopamine agonists decrease plasma prolactin levels and induce shrinkage in most patients and can be ceased in some of them. In patients with acromegaly, dopamine agonists, somatostatin analogues, and growth hormone receptor antagonist have been used as a monotherapy or the combination, and the high remission rate can be achieved. Pasireotide having high affinity to type 5 somatostatin receptors will be available for the patients presenting resistance against type 2 receptor agonists, such as octreotide and lanreotide. The preceding treatment with somatostatin analogues is beneficial for improving the success rate of TSS. The chimera compounds of somatostatin analogues and dopamine agonists have been investigated. The medical treatments of Cushing's disease are challenging, if TSS is not successful. To suppress ACTH secretion, dopamine agonists and somatostatin analogues have been examined, but neither came to show a sufficient effect. Pasireotide reduces urinary cortisol excretion with a high remission rate. Adrenal enzyme inhibitors (AEIs), such as metyrapone, can inhibit cortisol synthesis form adrenal glands promptly and sufficiently in most of patients. LCI699, a newly developed AEI, is more potent than metyrapone and will be available. We should use available medical treatments for improving the prognosis and quality of life. The Japan Neurosurgical Society 2014-12 2014-11-29 /pmc/articles/PMC4533360/ /pubmed/25446388 http://dx.doi.org/10.2176/nmc.ra.2014-0239 Text en © 2014 The Japan Neurosurgical Society This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Review Article
OKI, Yutaka
Medical Management of Functioning Pituitary Adenoma: An Update
title Medical Management of Functioning Pituitary Adenoma: An Update
title_full Medical Management of Functioning Pituitary Adenoma: An Update
title_fullStr Medical Management of Functioning Pituitary Adenoma: An Update
title_full_unstemmed Medical Management of Functioning Pituitary Adenoma: An Update
title_short Medical Management of Functioning Pituitary Adenoma: An Update
title_sort medical management of functioning pituitary adenoma: an update
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4533360/
https://www.ncbi.nlm.nih.gov/pubmed/25446388
http://dx.doi.org/10.2176/nmc.ra.2014-0239
work_keys_str_mv AT okiyutaka medicalmanagementoffunctioningpituitaryadenomaanupdate